FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800562246> ?p ?o ?g. }

• W2800562246 endingPage "1246" @default.
• W2800562246 startingPage "1239" @default.
• W2800562246 abstract "<h3>Background</h3> Ovarian cancer is associated with a high relapse rate and is the fifth leading cause of cancer deaths in women. The genetic profile of a tumor is responsible for deciding response to chemotherapeutic agents. In this study, we investigate the relation between survivin and p53 expression and response to chemotherapeutic agents of primary cultures of ovarian cancer cells established from ascitic fluid. <h3>Materials and Method</h3> Ascitic fluid and Dulbecco’s modified Eagle medium was mixed in equal proportion in culture flasks and incubated to establish primary culture. The cells were treated with different combinations of carboplatin and paclitaxel with and without survivin small interfering RNA transfection. Cell survival was estimated by MTT assay. Survivin and p53 expression was quantified by real-time polymerase chain reaction. <h3>Results</h3> Out of 19 ascitic fluid samples, 13 primary cultures of ovarian cancer cells were established. The half maximal inhibitory concentration doses of carboplatin (≥70 μg/mL) and paclitaxel (≥18 μg/mL) were high for 10/13 and 5/13 patients, respectively. Survivin messenger RNA expression was significantly downregulated on treatment with carboplatin (100 μg/mL), paclitaxel (12.5 μg/mL), and a combination of carboplatin (50 μg/mL) and paclitaxel (6.25 μg/mL). Only paclitaxel-treated ovarian cancer cells showed decrease in expression of p53. Survivin small interfering RNA increased sensitivity of the primary cultures to chemotherapeutic agents. <h3>Conclusions</h3> The present study highlights the fact that establishing primary cultures from ascitic fluid may help to develop personalized treatment regime for individual patients based on their molecular profile. Our study also shows that supplementing taxols drugs with survivin inhibitors may prove to be beneficial in the treatment of ovarian cancer patients." @default.
• W2800562246 created "2018-05-17" @default.
• W2800562246 creator A5005531453 @default.
• W2800562246 creator A5019312701 @default.
• W2800562246 creator A5036675464 @default.
• W2800562246 creator A5052287489 @default.
• W2800562246 creator A5059729874 @default.
• W2800562246 creator A5066387740 @default.
• W2800562246 creator A5070195820 @default.
• W2800562246 creator A5083953503 @default.
• W2800562246 date "2018-07-01" @default.
• W2800562246 modified "2023-10-14" @default.
• W2800562246 title "Role of Survivin and p53 Expression in Response of Primary Culture of Ovarian Cancer Cells to Treatment With Chemotherapeutic Agents" @default.
• W2800562246 cites W1492587973 @default.
• W2800562246 cites W1662899239 @default.
• W2800562246 cites W1757407923 @default.
• W2800562246 cites W1977540158 @default.
• W2800562246 cites W1979107980 @default.
• W2800562246 cites W1980676399 @default.
• W2800562246 cites W1985068997 @default.
• W2800562246 cites W1994941836 @default.
• W2800562246 cites W2003156928 @default.
• W2800562246 cites W2014199817 @default.
• W2800562246 cites W2025766222 @default.
• W2800562246 cites W2027730833 @default.
• W2800562246 cites W2035471588 @default.
• W2800562246 cites W2041056208 @default.
• W2800562246 cites W2042565470 @default.
• W2800562246 cites W2044139691 @default.
• W2800562246 cites W2044822742 @default.
• W2800562246 cites W2053992683 @default.
• W2800562246 cites W2055069783 @default.
• W2800562246 cites W2057954774 @default.
• W2800562246 cites W2066441074 @default.
• W2800562246 cites W2075083788 @default.
• W2800562246 cites W2083540484 @default.
• W2800562246 cites W2089662123 @default.
• W2800562246 cites W2092105822 @default.
• W2800562246 cites W2094965284 @default.
• W2800562246 cites W2097777938 @default.
• W2800562246 cites W2100894466 @default.
• W2800562246 cites W2101525290 @default.
• W2800562246 cites W2127952549 @default.
• W2800562246 cites W2145555831 @default.
• W2800562246 cites W2148220182 @default.
• W2800562246 cites W2168851383 @default.
• W2800562246 cites W2204583106 @default.
• W2800562246 cites W2281427448 @default.
• W2800562246 cites W2746894177 @default.
• W2800562246 cites W4254357547 @default.
• W2800562246 cites W4255762755 @default.
• W2800562246 doi "https://doi.org/10.1097/igc.0000000000001281" @default.
• W2800562246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29727353" @default.
• W2800562246 hasPublicationYear "2018" @default.
• W2800562246 type Work @default.
• W2800562246 sameAs 2800562246 @default.
• W2800562246 citedByCount "7" @default.
• W2800562246 countsByYear W28005622462019 @default.
• W2800562246 countsByYear W28005622462021 @default.
• W2800562246 countsByYear W28005622462022 @default.
• W2800562246 countsByYear W28005622462023 @default.
• W2800562246 crossrefType "journal-article" @default.
• W2800562246 hasAuthorship W2800562246A5005531453 @default.
• W2800562246 hasAuthorship W2800562246A5019312701 @default.
• W2800562246 hasAuthorship W2800562246A5036675464 @default.
• W2800562246 hasAuthorship W2800562246A5052287489 @default.
• W2800562246 hasAuthorship W2800562246A5059729874 @default.
• W2800562246 hasAuthorship W2800562246A5066387740 @default.
• W2800562246 hasAuthorship W2800562246A5070195820 @default.
• W2800562246 hasAuthorship W2800562246A5083953503 @default.
• W2800562246 hasConcept C121608353 @default.
• W2800562246 hasConcept C126322002 @default.
• W2800562246 hasConcept C143998085 @default.
• W2800562246 hasConcept C22615655 @default.
• W2800562246 hasConcept C2775975398 @default.
• W2800562246 hasConcept C2776694085 @default.
• W2800562246 hasConcept C2777292972 @default.
• W2800562246 hasConcept C2778239845 @default.
• W2800562246 hasConcept C2780427987 @default.
• W2800562246 hasConcept C2781451048 @default.
• W2800562246 hasConcept C502942594 @default.
• W2800562246 hasConcept C54009773 @default.
• W2800562246 hasConcept C54355233 @default.
• W2800562246 hasConcept C71924100 @default.
• W2800562246 hasConcept C81885089 @default.
• W2800562246 hasConcept C86803240 @default.
• W2800562246 hasConceptScore W2800562246C121608353 @default.
• W2800562246 hasConceptScore W2800562246C126322002 @default.
• W2800562246 hasConceptScore W2800562246C143998085 @default.
• W2800562246 hasConceptScore W2800562246C22615655 @default.
• W2800562246 hasConceptScore W2800562246C2775975398 @default.
• W2800562246 hasConceptScore W2800562246C2776694085 @default.
• W2800562246 hasConceptScore W2800562246C2777292972 @default.
• W2800562246 hasConceptScore W2800562246C2778239845 @default.
• W2800562246 hasConceptScore W2800562246C2780427987 @default.
• W2800562246 hasConceptScore W2800562246C2781451048 @default.
• W2800562246 hasConceptScore W2800562246C502942594 @default.
• W2800562246 hasConceptScore W2800562246C54009773 @default.

• next